Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyfuse Biomedical KKTSE:4892 -4.09%53 PS Ratio is 154.37 as of Jul. 17, 2026, which is 4% below its 10-year median of 160.96. GuruFocus rates TSE:4892 with a GF Score™ of 53/100 and a GF Value™ of 円2,174.28 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 954 Drug Manufacturers companies, Cyfuse Biomedical KK ranks worse than 98.53% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cyfuse Biomedical KK's share price is 円540.00.
Cyfuse Biomedical KK's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円3.50. Hence, Cyfuse Biomedical KK's PS Ratio for today is 154.37.
Good Sign:
Cyfuse Biomedical KK stock PS Ratio (=20.58) is close to 5-year low of 20.58.
The historical rank and industry rank for Cyfuse Biomedical KK's PS Ratio or its related term are showing as below:
TSE:4892'
s PS Ratio Range Over the Past 10 Years
Min: 58.71 Med: 160.96 Max: 1923.54
Current: 154.37
During the past 6 years, Cyfuse Biomedical KK's highest PS Ratio was 1923.54. The lowest was 58.71. And the median was 160.96.
TSE:4892's PS Ratio is ranked worse than 98.53% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs TSE:4892: 154.37
Cyfuse Biomedical KK revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Cyfuse Biomedical KK was 288.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -42.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -39.10% per year.
During the past 6 years, Cyfuse Biomedical KK's highest 3-Year average Revenue per Share Growth Rate was -25.80% per year. The lowest was -83.20% per year. And the median was -42.80% per year.
Back to Basics: PS Ratio
Cyfuse Biomedical KK (TSE:4892) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cyfuse Biomedical KK PS Ratio Related Terms
Cyfuse Biomedical KK PS Ratio Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cyfuse Biomedical KK's Share Price of today is 円540.00. Cyfuse Biomedical KK's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cyfuse Biomedical KK (TSE:4892) has a PS Ratio of 154.37 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cyfuse Biomedical KK and its competitors. This is near median its historical median of 160.96. Over the past decade, Cyfuse Biomedical KK's PS Ratio has ranged from 58.71 to 1,923.54. According to the industry distribution chart, Cyfuse Biomedical KK ranks #940 out of 954 companies in the Drug Manufacturers industry, placing it in the top 98.5%.
Is Cyfuse Biomedical KK's PS Ratio too high?
Cyfuse Biomedical KK's current PS Ratio of 154.37 is near median its 10-year median of 160.96. Over the past 10 years, this metric has ranged from a low of 58.71 to a high of 1,923.54. The Drug Manufacturers industry median PS Ratio is 2.33. Cyfuse Biomedical KK's value of 154.37 is 6539.6% above this industry median. Based on the distribution chart, Cyfuse Biomedical KK ranks #940 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #940 out of 954 companies for PS Ratio. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median PS Ratio is 2.33. Cyfuse Biomedical KK's value of 154.37 is 6539.6% above this benchmark. Historically, Cyfuse Biomedical KK's own PS Ratio has ranged from 58.71 to 1,923.54 over the past decade. While the company's 10-year median is 160.96 vs. the industry median of 2.33, Cyfuse Biomedical KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyfuse Biomedical KK's current PS Ratio of 154.37 is 6539.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current PS Ratio is 154.37, which is near median its own 10-year median of 160.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,174.28, compared to a current price of 円540.00 — trading 75.2% below its estimated fair value. The current PS Ratio is 154.37, which is near median its 10-year median of 160.96 and 6539.6% above the Drug Manufacturers industry median of 2.33. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current PS Ratio is 154.37 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円540.00 is trading 75.2% below its estimated GF Value™ of 円2,174.28.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
PS Ratio: 154.37 (near median its 10-year median of 160.96)
GF Value™: 円2,174.28 vs. price of 円540.00 (75.2% below fair value)
Industry Position: 6539.6% above the Drug Manufacturers median (#940 of 954)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
